

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

Case No. 3428

NORTH HIGHLANDS PHARMACY

5600 Watt Avenue
North Highlands, CA 95660

Pharmacy Permit Number PHY 39917

and

THOMAS OKIMOTO

5600 Watt Avenue
North Highlands, CA 95660

Pharmacist License No. RPH 24559

Respondent.

DECISION AND ORDER


The attached Stipulated Surrender of License and Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This decision shall become effective on January 13, 2014.

It is so ORDERED on December 13, 2013.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By



STAN C. WEISSER
Board President

1 KAMALA D. HARRIS
Attorney General of California
2 JANICE LACHMAN
Supervising Deputy Attorney General
3 LORRIE M. YOST
Deputy Attorney General
4 State Bar No. 119088
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 445-2271
Facsimile: (916) 327-8643
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 3428

13 NORTH HIGHLANDS PHARMACY
5600 Watt Avenue
North Highlands, CA 95660

OAH No. 2012080165

14 Pharmacy Permit Number PHY 39917

**STIPULATED SURRENDER OF
LICENSE AND ORDER**

15 and

16 THOMAS OKIMOTO
5600 Watt Avenue
17 North Highlands, CA 95660

18 Pharmacist License Number RPH 24559

19 Respondents.

20
21 IT IS HEREBY STIPULATED AND AGREED by and between the parties in this
22 proceeding that the following matters are true:

23 PARTIES

24 1. Virginia Herold (Complainant) is the Executive Officer of the Board of Pharmacy.
25 She brought this action solely in her official capacity and is represented in this matter by Kamala
26 D. Harris, Attorney General of the State of California, by Lorrie M. Yost, Deputy Attorney
27 General.

28 ///

2. North Highlands Pharmacy and Thomas Okimoto are represented in this proceeding by attorney Richard T. Dudek, whose address is 901 H Street, Suite 301, Sacramento, CA 95814.

3. On or about August 30, 1994, the Board of Pharmacy (Board) issued Pharmacy Permit Number PHY 39917 to North Highlands Pharmacy, Inc., d.b.a. North Highlands Pharmacy; Thomas Okimoto, President, Pharmacist-In-Charge, (Respondent North Highlands). The pharmacy permit was in full force and effect at all times relevant to the charges brought herein and will expire on August 1, 2013, unless renewed.

4. On or about July 25, 1966, the Board of Pharmacy issued Pharmacist License Number RPH 24559 to Thomas Okimoto (Respondent Okimoto). The pharmacist license was in full force and effect at all times relevant to the charges brought herein and will expire on February 29, 2014, unless renewed.

JURISDICTION

5. Accusation No. 3428 was filed before the Board of Pharmacy (Board), Department of Consumer Affairs, and is currently pending against Respondents North Highlands and Okimoto. The Accusation and all other statutorily required documents were properly served on both Respondents on April 19, 2012. Respondents timely filed their Notice of Defense contesting the Accusation. A copy of Accusation No. 3428 is attached as Exhibit A and incorporated by reference.

ADVISEMENT AND WAIVERS

6. Respondents North Highlands and Okimoto have carefully read, fully discussed with counsel, and understand the charges and allegations in Accusation No. 3428. Respondents also have carefully read, fully discussed with counsel, and understand the effects of this Stipulated Surrender of License and Order.

7. Respondents North Highlands and Okimoto are fully aware of their legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to be represented by counsel at their own expense; the right to confront and cross-examine the witnesses against them; the right to present evidence and to testify on their own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of

1 documents; the right to reconsideration and court review of an adverse decision; and all other
2 rights accorded by the California Administrative Procedure Act and other applicable laws.

3 8. Respondents North Highlands and Okimoto voluntarily, knowingly, and intelligently
4 waive and give up each and every right set forth above.

5 CULPABILITY

6 9. For the purpose of resolving the Accusation without the expense and uncertainty of
7 further proceedings, Respondents North Highlands and Okimoto admit that, at a hearing,
8 Complainant could establish a factual basis for the charges and allegations in Accusation No.
9 3428, and that those charges and allegations are cause for discipline. Respondents feel that they
10 could present a defense against the charges but none the less hereby give up their right to contest
11 those charges and allegations in order to resolve this matter.

12 10. Respondents North Highlands and Okimoto understand that the charges and
13 allegations in Accusation No. 3428, if proven at a hearing, constitute cause for imposing
14 discipline upon Pharmacy Permit Number PHY 39917 and Pharmacist License Number RPH
15 24559.

16 11. Respondent North Highlands Pharmacy understands that by signing this stipulation it
17 enables the Board to issue an order accepting the surrender of its pharmacy permit without further
18 process.

19 12. Respondent Thomas Okimoto understands that by signing the stipulation he enables
20 the Board to issue an order accepting the surrender of his pharmacist license without further
21 process.

22 CONTINGENCY

23 13. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents
24 North Highlands and Okimoto understand and agree that counsel for Complainant and the staff of
25 the Board of Pharmacy may communicate directly with the Board regarding this stipulation and
26 surrender, without notice to or participation by Respondents or their counsel. By signing the
27 stipulation, Respondents understand and agree that they may not withdraw their agreement or
28 seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board

1 fails to adopt this stipulation as its Decision and Order, the Stipulated Surrender and Disciplinary
2 Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal
3 action between the parties, and the Board shall not be disqualified from further action by having
4 considered this matter.

5 14. The parties understand and agree that facsimile copies of this Stipulated Surrender of
6 License and Order, including facsimile signatures thereto, shall have the same force and effect as
7 the originals.

8 15. This Stipulated Surrender of License and Order is intended by the parties to be an
9 integrated writing representing the complete, final, and exclusive embodiment of their agreement.
10 It supersedes any and all prior or contemporaneous agreements, understandings, discussions,
11 negotiations, and commitments (written or oral). This Stipulated Surrender of License and Order
12 may not be altered, amended, modified, supplemented, or otherwise changed except by a writing
13 executed by an authorized representative of each of the parties.

14 16. In consideration of the foregoing admissions and stipulations, the parties agree that
15 the Board may, without further notice or formal proceeding, issue and enter the following Order:

16 **ORDER**

17 IT IS HEREBY ORDERED that Pharmacy Permit Number PHY 39917 to North Highlands
18 Pharmacy; Thomas Okimoto, Pharmacist-in-Charge and Pharmacist License Number RPH 24559
19 to Thomas Okimoto shall be surrendered and accepted by the Board of Pharmacy. The surrender
20 of the licenses shall take place as of the effective date of the Board's Decision and Order.

21 1. The surrender of Respondent North Highlands' Pharmacy Permit Number PHY
22 39917, and the surrender of Respondent Okimoto's Pharmacist License Number RPH 24559, and
23 the acceptance of the surrendered licenses by the Board shall constitute the imposition of
24 discipline against Respondents. This stipulation constitutes a record of the discipline and shall
25 become a part of Respondents' license history with the Board of Pharmacy.

26 2. Respondent North Highlands Pharmacy shall lose all rights and privileges as a
27 pharmacy in California as the effective date of the Board's Decision and Order.

28 ///

1 3. Respondent Thomas Okimoto shall lose all rights and privileges as a pharmacist in
2 California as the effective date of the Board's Decision and Order.

3 4. Respondents North Highlands and Okimoto shall cause to be delivered to the Board
4 their pocket licenses and, if one was issued, its wall certificates, on or before the effective date of
5 the surrender of their pharmacy permit and pharmacist license.

6 5. If the pharmacy has not yet been transferred at the time of the effective date of this
7 decision, then within 30 days of the effective date of the decision, Respondent North Highlands
8 shall employ a consulting pharmacist to assist with maintaining the pharmacy's compliance with
9 all applicable pharmacy laws and regulations. Prior to the employment of this consultant,
10 Respondent North Highlands shall submit the name of the candidate(s) for the position of
11 consulting pharmacist to the Board for approval. Respondent shall submit the name of another
12 candidate for the position of consulting pharmacist within seven days of the Board's decision, in
13 the event that Respondent's first or subsequent requests are denied.

14 6. If either Respondent North Highlands or Okimoto ever files an application for
15 licensure or a petition for reinstatement in the State of California, the Board shall treat it as a new
16 application for licensure. Respondents must comply with all the laws, regulations and procedures
17 for application for a new license in effect at the time the petition is filed, and all of the charges
18 and allegations contained in Accusation No. 3428 shall be deemed to be true, correct and
19 admitted when the Board determines whether to grant or deny the petition.

20 7. Respondent Okimoto agrees that, once the pharmacy is sold, he will no longer have
21 any involvement with the pharmacy as a consultant, employee or volunteer.

22 8. The Board shall waive its costs of investigation and prosecution of this matter.

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


ENDORSEMENT

The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted
for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

Dated: 10.25.2013

Respectfully submitted,

KAMALA D. HARRIS
Attorney General of California
JANICE LACHMAN
Supervising Deputy Attorney General


LORRIE M. YOST
Deputy Attorney General
Attorneys for Complainant

SA2009102211
11045728.doc

Exhibit A

Accusation No. 3428

1 KAMALA D. HARRIS
Attorney General of California
2 JANICE K. LACHMAN
Supervising Deputy Attorney General
3 LORRIE M. YOST
Deputy Attorney General
4 State Bar No. 119088
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 445-2271
Facsimile: (916) 327-8643
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 3428

13 NORTH HIGHLANDS PHARMACY
5600 Watt Avenue
North Highlands, CA 95660

ACCUSATION

14 Pharmacy Permit Number PHY 39917

15 and

16 THOMAS OKIMOTO
5600 Watt Avenue
17 North Highlands, CA 95660

18 Pharmacist License Number RPH 24559

19 Respondents.

20
21 Complainant alleges:

22 PARTIES

23 1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity
24 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

25 2. On or about August 30, 1994, the Board of Pharmacy (Board) issued Pharmacy Permit
26 Number PHY 39917 to North Highlands Pharmacy; Thomas Okimoto, Pharmacist-In-Charge,
27 (Respondent North Highlands). Thomas Okimoto has been the Pharmacist-In-Charge since

28 ///

1 August 30, 1994. The pharmacy permit was in full force and effect at all times relevant to the
2 charges brought herein and will expire on August 1, 2012, unless renewed.

3 3. On or about July 25, 1966, the Board of Pharmacy issued Pharmacist License
4 Number RPH 24559 to Thomas Okimoto (Respondent Okimito). The pharmacist license was in
5 full force and effect at all times relevant to the charges brought herein and will expire on February
6 29, 2014, unless renewed.

7 JURISDICTION

8 4. This Accusation is brought before the Board of Pharmacy (Board), Department of
9 Consumer Affairs, under the authority of the following laws. All section references are to the
10 Business and Professions Code unless otherwise indicated.

11 STATUTORY PROVISIONS

12 5. Section 4063 of the Code states:

13 "No prescription for any dangerous drug or dangerous device may be refilled except upon
14 authorization of the prescriber. The authorization may be given orally or at the time of giving the
15 original prescription. No prescription for any dangerous drug that is a controlled substance may
16 be designated refillable as needed."

17 6. Section 4076 of the Code states in pertinent part:

18 "(a) A pharmacist shall not dispense any prescription except in a container that meets the
19 requirements of state and federal law and is correctly labeled with all of the following:

20 (11)(A) Commencing January 1, 2006, the physical description of the dispensed
21 medication, including its color, shape, and any identification code that appears on the tablets or
22 capsules

23 (C) The information required by this paragraph may be printed on an auxiliary label that is
24 affixed to the prescription container."

25 7. Section 4077 of the Code states in pertinent part:

26 (a) Except as provided in subdivisions (b) and (c), no person shall dispense any dangerous
27 drug upon prescription except in a container correctly labeled with the information required by
28 Section 4076."

1 8. Section 4081 of the Code states in pertinent part:

2 "(a) All records of manufacture and of sale, acquisition, or disposition of dangerous drugs
3 or dangerous devices shall be at all times during business hours open to inspection by authorized
4 officers of the law, and shall be preserved for at least three years from the date of making. A
5 current inventory shall be kept by every manufacturer, wholesaler, pharmacy, veterinary
6 food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital,
7 institution, or establishment holding a currently valid and unrevoked certificate, license, permit,
8 registration, or exemption under Division 2 (commencing with Section 1200) of the Health and
9 Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and
10 Institutions Code who maintains a stock of dangerous drugs or dangerous devices."

11 9. Section 4105 of the Code states in pertinent part:

12 "(a) All records or other documentation of the acquisition and disposition of dangerous
13 drugs and dangerous devices by any entity licensed by the board shall be retained on the licensed
14 premises in a readily retrievable form."

15 10. Section 4113 of the Code states in pertinent part:

16 "(c) The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all
17 state and federal laws and regulations pertaining to the practice of pharmacy."

18 11. Section 4300 of the Code states in pertinent part:

19 "(a) Every license issued may be suspended or revoked.

20 (b) The board shall discipline the holder of any license issued by the board, whose default
21 has been entered or whose case has been heard by the board and found guilty, by any of the
22 following methods:

23 (1) Suspending judgment.

24 (2) Placing him or her upon probation.

25 (3) Suspending his or her right to practice for a period not exceeding one year.

26 (4) Revoking his or her license.

27 (5) Taking any other action in relation to disciplining him or her as the board in its
28 discretion may deem proper.

1 “(e) The proceedings under this article shall be conducted in accordance with Chapter 5
2 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board
3 shall have all the powers granted therein. The action shall be final, except that the propriety of
4 the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of
5 Civil Procedure.”

6 12. Section 4301 of the Code states in pertinent part:

7 “The board shall take action against any holder of a license who is guilty of unprofessional
8 conduct or whose license has been procured by fraud or misrepresentation or issued by mistake.
9 Unprofessional conduct shall include, but is not limited to, any of the following:

10 (j) The violation of any of the statutes of this state, or any other state, or of the United
11 States regulating controlled substances and dangerous drugs.

12 (o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the
13 violation of or conspiring to violate any provision or term of this chapter or of the applicable
14 federal and state laws and regulations governing pharmacy, including regulations established by
15 the board or by any other state or federal regulatory agency.”

16 13. Section 4342 of the Code states in pertinent part:

17 “(a) The board may institute any action or actions as may be provided by law and that, in
18 its discretion, are necessary, to prevent the sale of pharmaceutical preparations and drugs that do
19 not conform to the standard and tests as to quality and strength, provided in the latest edition of
20 the United States Pharmacopoeia or the National Formulary, or that violate any provision of the
21 Sherman Food, Drug and Cosmetic Law (Part 5 (commencing with Section 109875) of Division
22 104 of the Health and Safety Code).”

23 14. California Code of Regulations, Title 16 (16 CCR), section 1714 states in pertinent
24 part:

25 “(b) Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and
26 equipment so that drugs are safely and properly prepared, maintained, secured and distributed.
27 The pharmacy shall be of sufficient size and unobstructed area to accommodate the safe practice
28 of pharmacy.

1 (c) The pharmacy and fixtures and equipment shall be maintained in a clean and orderly
2 condition. The pharmacy shall be dry, well-ventilated, free from rodents and insects, and properly
3 lighted. The pharmacy shall be equipped with a sink with hot and cold running water for
4 pharmaceutical purposes."

5 15. 16 CCR section 1715 states in pertinent part:

6 "(a) The pharmacist-in-charge of each pharmacy as defined under section 4029 or section
7 4037 of the Business and Professions Code shall complete a self-assessment of the pharmacy's
8 compliance with federal and state pharmacy law. The assessment shall be performed before July 1
9 of every odd-numbered year. The primary purpose of the self-assessment is to promote
10 compliance through self-examination and education.

11 (d) Each self-assessment shall be kept on file in the pharmacy for three years after it is
12 performed."

13 16. 16 CCR section 1716 states in pertinent part:

14 "Pharmacists shall not deviate from the requirements of a prescription except upon the prior
15 consent of the prescriber or to select the drug product in accordance with Section 4073 of the
16 Business and Professions Code."

17 17. 16 CCR section 1745 states in pertinent part:

18 "(a) A prescription for a Schedule II controlled substance (as defined in Health and Safety
19 Code section 11055) may be partially filled, as defined in paragraph (b), if:

20 (1) The prescription is for an inpatient of a skilled nursing facility as defined in Health and
21 Safety Code section 1250; or

22 (2) The prescription is for a terminally ill patient. "Terminally ill" as used herein means a
23 patient for whom a licensed physician and surgeon has made and documented a diagnosis of
24 illness or disease that will result in death.

25 (b) A "partially filled" prescription is a prescription from which only a portion of the
26 amount for which the prescription is written is filled at any one time; provided that regardless of
27 how many times the prescription is partially filled, the total amount dispensed shall not exceed
28 that written on the face of the prescription.

1 (d) A pharmacist may partially fill a prescription for a controlled substance listed in
2 Schedule II, if the pharmacist is unable to supply the full quantity ordered by the prescriber. The
3 pharmacist shall make a notation of the quantity supplied on the face of the written prescription.
4 The remaining portion of the prescription may be filled within 72 hours of the first partial filling.
5 If the remaining portion is not filled within the 72-hour period, the pharmacist shall notify the
6 prescriber. The pharmacist may not supply the drug after 72 hour period has expired without a
7 new prescription."

8 18. 16 CCR section 1761 states:

9 "(a) No pharmacist shall compound or dispense any prescription which contains any
10 significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any
11 such prescription, the pharmacist shall contact the prescriber to obtain the information needed to
12 validate the prescription.

13 (b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense
14 a controlled substance prescription where the pharmacist knows or has objective reason to know
15 that said prescription was not issued for a legitimate medical purpose."

16 19. Health and Safety Code section 11165, subdivision (d) provides in pertinent part:

17 "(d) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled
18 substance, the dispensing pharmacy or clinic shall provide the following information to the
19 Department of Justice on a weekly basis and in a format specified by the Department of Justice:

20 (1) Full name, address, and the telephone number of the ultimate user or research subject, or
21 contact information as determined by the Secretary of the United States Department of Health and
22 Human Services, and the gender, and date of birth of the ultimate user.

23 (2) The prescriber's category of licensure and license number; federal controlled substance
24 registration number; and the state medical license number of any prescriber using the federal
25 controlled substance registration number of a government-exempt facility.

26 (3) Pharmacy prescription number, license number, and federal controlled substance
27 registration number.

28 (4) NDC (National Drug Code) number of the controlled substance dispensed.

1 (5) Quantity of the controlled substance dispensed.

2 (6) ICD-9 (diagnosis code), if available.

3 (7) Number of refills ordered.

4 (8) Whether the drug was dispensed as a refill of a prescription or as a first-time request.

5 (9) Date of origin of the prescription.

6 (10) Date of dispensing of the prescription.”

7 20. 16 CCR section 1793.7 states in pertinent part:

8 “(d) Any pharmacy employing or using a pharmacy technician shall develop a job
9 description and written policies and procedures adequate to ensure compliance with the
10 provisions of Article 11 of this Chapter, and shall maintain, for at least three years from the time
11 of making, records adequate to establish compliance with these sections and written policies and
12 procedures.”

13 21. Section 118, subdivision (b), of the Code provides that the expiration of a license
14 shall not deprive the Board of jurisdiction to proceed with a disciplinary action during the period
15 within which the license may be renewed, restored, reissued or reinstated.

16 22. Section 125.3 of the Code provides, in pertinent part, that the Board may request the
17 administrative law judge to direct a licensee found to have committed a violation or violations of
18 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
19 enforcement of the case.

20 CONTROLLED SUBSTANCES/DANGEROUS DRUGS AT ISSUE

21 23. Hydrocodone with acetaminophen (HC/AP) is a pain medication classified as a
22 Schedule III controlled substance pursuant to Health and Safety Code section 11506, subdivision
23 (e)(4), and as a dangerous drug pursuant to Business and Professions Code section 4022.

24 24. OxyContin contains oxycodone which is an opioid agonist and a Schedule II
25 controlled substance under Health and Safety Code section 11055, subdivision (b)(1)(N), as well
26 as a dangerous drug pursuant to Business and Professions Code section 4022.

27 25. Fentanyl is a synthetic narcotic analgesic and a Schedule II controlled substance
28 under Health and Safety Code section 11055 subdivision (c)(8), as well as a dangerous drug

1 pursuant to Business and Professions Code section 4022. The Fentanyl transdermal patch is used
2 in chronic pain management.

3 FIRST CAUSE FOR DISCIPLINE

4 (Erroneous Or Uncertain Prescriptions)

5 26. Respondents Highlands and Okimoto are subject to disciplinary action under 16 CCR
6 section 1761, subdivisions (a) and (b) as that section interacts with Code section 4301,
7 subdivision (o) in that Respondent PIC Okimoto dispensed uncertain or ambiguous prescriptions
8 for a controlled substance when Respondent PIC Okimoto knew or should have known that the
9 prescriptions were not issued for a legitimate medical purpose. The circumstances are as that
10 Respondent PIC Okimoto filled prescriptions for patients who were consuming the prescribed
11 drugs at a rate significantly higher than that which was prescribed and/or the maximum
12 recommended dose, without questioning the medical purpose or directions for proper use of these
13 drugs, as follows:

14 a. From approximately November 4, 2007 to July 04, 2009, PIC Okimoto furnished
15 11,727 tablets of HC/AP 10/325 to Patient S.D. The average number of tablets consumed per day
16 was 19.3, approximately 60% more than the 12 tablets a day that had been prescribed by the
17 patient's physician. The daily average of 19 tablets also equaled 6.3 grams of HC/AP per day,
18 approximately 58% more than the maximum recommended dosage.

19 b. From approximately December 5, 2007 to June 25, 2009, with regard to 17 out of 33
20 prescriptions, PIC Okimoto furnished 8430 HC/AP 10/325 tablets to Patient L.F. The average
21 number of tablets consumed per day was 14.8, approximately 23% more than the maximum of the
22 6 to 12 tablets a day that had been prescribed by the patient's physician. Furthermore, with
23 respect to 21 prescriptions filled for Patient LF, the average daily usage of HC/AP 10/325 was 6.2
24 grams, approximately 55% more than the maximum recommended dosage.

25 c. From approximately September 26, 2007 to June 23, 2009, PIC Okimoto furnished 48
26 prescriptions totaling 4,950 HC/AP 10/325 tablets to Patient W.H. The average daily
27 consumption was 7.8 tablets per day, approximately 95% more than the prescribed maximum of 4
28 tablets a day.

1 d. From approximately November 20, 2007 to October 23, 2008, PIC Okimoto
2 furnished 25 prescriptions for HC/AP 10/325, a total of 4,340 tablets, to Patient M.W. This
3 averaged 13.2 tablets per day, approximately 10% more than the prescribed 12 tablets a day. This
4 also equaled 4.29 grams of HC/AP 10/325 per day, approximately 7% more than the maximum
5 recommended dosage and 10% more than prescribed.

6 27. Respondents Highlands and Okimoto are subject to disciplinary action under section
7 16 CCR section 1761, subdivisions (a) and (b) as that section interacts with Code section 4301,
8 subdivision (o) in that Respondent PIC Okimoto dispensed uncertain or ambiguous prescriptions
9 for a controlled substance when Respondent PIC Okimoto knew or should have known that the
10 prescriptions were not issued for a legitimate medical purpose. The circumstances are as that
11 Respondent PIC Okimoto furnished duplicate prescriptions less than 30 days apart, frequently for
12 two different strengths of HC/AP, to patients who simultaneously held an older refill prescription
13 for HC/AP and a new prescription for HC/AP, without questioning which prescription was the
14 appropriate one, as follows:

15 a. From approximately January 19, 2007 to November, 15, 2008, PIC Charge Okimoto
16 furnished the following erroneous or uncertain duplicitous prescriptions for HC/AP to Patient L.F.:

17 i. On January 19, 2008, PIC Okimoto furnished to Patient L.F. 150 tablets of
18 HC/AP 7.5/750 from refill prescription number 1233896, which he should have
19 known to be erroneous or uncertain because on that same day he already furnished
20 to Patient L.F. 360 tablets of HC/AP 10/325 from new prescription number
21 1236926.

22 ii. On February 11, 2008, PIC Okimoto furnished to Patient L.F. 150 tablets of
23 HC/AP 7.5/750 from refill prescription number 1233896 which he should have
24 known to be erroneous or uncertain because on that same day he already furnished
25 to Patient L.F. 360 tablets of HC/AP 10/325 from refill prescription number
26 1236926 for 360 tablets of HC/AP 10/325.

27 iii. On April 24, 2008, PIC Okimoto furnished to Patient L.F. 150 tablets of HC/AP
28 7.5/750 from refill prescription number 1240670, which he should have known to be

erroneous or uncertain because on April 8, 2008, PIC Okimoto had already furnished to Patient L.F. 360 tablets of HC/AP 10/325 from new prescription number 1242692.

iv. On May 16, 2008, PIC Okimoto furnished to Patient L.F. 150 tablets of HC/AP 7.5/750 from refill prescription number 1240670, which he should have known to be erroneous or uncertain because on May 5, 2008, PIC Okimoto had already furnished to Patient L.F. 360 tablets of HC/AP 10/325 from new prescription number 1242692.

v. On July 1, 2008, PIC Okimoto furnished to Patient L.F. 360 tablets of HC/AP 10/325 from refill prescription number 1242692, which he should have known to be erroneous or uncertain because on June 24, 2008, he had already furnished to Patient L.F. 150 tablets of HC/AP 7.5/750 from new prescription number 1247740.

vi. On August 13, 2008, PIC Okimoto furnished to Patient L.F. 150 tablets of HC/AP 7.5/750 from refill prescription number 1247740, which he should have known to be erroneous or uncertain because on July 31, 2008, he had already furnished to Patient L.F. 360 tablets of HC/AP 10/325 from new prescription number 1249897.

vii. On September 12, 2008, PIC Okimoto furnished to Patient L.F. 150 tablets of HC/AP 7.5/750 from refill prescription number 1247740, which he should have known to be erroneous or uncertain because on August 30, 2008, he had already furnished to Patient L.F. 360 tablets of HC/AP 10/325 from refill prescription number 1249897.

viii. On October 28, 2008, PIC Okimoto furnished to Patient L.F. 360 tablets of HC/AP 10/325 from refill prescription number 1252983, which he should have known to be erroneous or uncertain because on October 2, 2008, he had already furnished to Patient L.F. 150 tablets of HC/AP 7.5/750 from new prescription number 1253608.

///

- ix. On November 15, 2008, PIC Okimoto furnished to Patient L.F. 360 tablets of HC/AP 10/325 from refill prescription number 1252983, which he should have known to be erroneous or uncertain because on October 2, 2008, he had already furnished to Patient L.F. 150 tablets of HC/AP 7.5/750 from new prescription number 1253608.
- b. From approximately September 26, 2007 to June 23, 2009, PIC Charge Okimoto furnished erroneous or uncertain duplicate prescriptions for HC/AP to Patient W.H. as follows:
- i. On October 23, 2007, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1229475, which he should have known to be erroneous or uncertain because on October 10, 2007, he had already furnished to Patient W.H. 90 tablets of HC/AP 5/325, from new prescription number 1230291.
- ii. On November 19, 2007, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325, from refill prescription number 1229475, which he should have known was erroneous or uncertain because on November 08, 2007, he had already furnished to Patient W.H. 90 tablets of HC/AP 5/325, from new prescription number 1230291.
- iii. On January 7, 2008, and February 1, 2008, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1234646, which he should have known to be erroneous or uncertain because on January 3, 2008, he had already furnished to Patient W.H. 90 tablets of HC/AP 5/500 from new prescription number 1235692.
- iv. On March 1, 2008, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325, from refill prescription number 1234646, which he should have known was erroneous or uncertain because on February 4, 2008, he had already furnished 90 tablets of HC/AP 5/325 to Patient W.H. from refill prescription number 1235692.
- v. On May 5, 2008, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1234646, which he should have known was

erroneous or uncertain because on April 19, 2008, he had already furnished to Patient W.H. 90 tablets of HC/AP 5/500 from new prescription number 1241891.

vi. On May 30, 2008, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1234646, which he should have known was erroneous or uncertain because on May 16, 2008, he furnished to Patient W.H. 90 tablets of HC/AP 5/500 from refill prescription number 1241990.

vii. On July 14, 2008, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1247277, which he should have known was erroneous or uncertain because on June 27, 2008, he had already furnished to Patient W.H. 120 tablets of HC/AP 5/500 from new prescription number 1247972.

viii. On August 20, 2008, PIC Okimoto furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription number 1247972, which he should have known was erroneous or uncertain because on August 5, 2008, he had already furnished to Patient W.H. 90 tablets of HC/AP 5/325 from new prescription number 1250114.

ix. On September 19, 2008, PIC Okimoto furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription number 1247972, which he should have known was erroneous or uncertain because on September 2, 2008, he had already furnished to Patient W.H. 90 tablets from refill prescription number 1250114.

x. On October 13, 2008, PIC Okimoto furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription number 1247972, which he should have known was erroneous or uncertain because on October 1, 2008, he had already furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1250114.

xi. On December 2, 2008, PIC Okimoto furnished to Patient W.H. 90 tablets of HC/AP 5/325 from refill prescription number 1250114, which he should have known was erroneous or uncertain because on November 17, 2008, furnished to Patient W.H. 90 tablets of HC/AP 5/500 from new prescription number 1256539.

1 xii. On December 26, 2008, PIC Okimoto furnished to Patient W.H. 120 tablets of
2 HC/AP 5/325 from refill prescription number 1256159, which he should have
3 known was erroneous or uncertain because on December 09, 2008, he had already
4 furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription
5 number 1256539.

6 xiii. On January 29, 2009, PIC Okimoto furnished to Patient W.H. 120 tablets of
7 HC/AP 5/325 from refill prescription number 1256159, which he should have
8 known was erroneous or uncertain because on January 13, 2009, he had already
9 furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription
10 number 1256539.

11 xiv. On February 23, 2009, PIC Okimoto furnished to Patient W.H. 120 tablets of
12 HC/AP 5/325 from refill prescription number 1256159, which he should have
13 known was erroneous or uncertain because on February 12, 2009, he had already
14 furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription
15 number 1256539.

16 xv. On March 20, 2009, PIC Okimoto furnished to Patient W.H. 120 tablets of
17 HC/AP 5/325 from refill prescription number 1256159, which he should have
18 known was erroneous or uncertain because on March 11, 2009, he had already
19 furnished to Patient W.H. 120 tablets of HC/AP 5/500 from new prescription
20 number 1264414.

21 xvi. On April 21, 2009, PIC Okimoto furnished to Patient W.H. 120 tablets of
22 HC/AP 5/325 from refill prescription number 1256159, which he should have
23 known was erroneous or uncertain because on April 7, 2009, he had already
24 furnished to Patient W.H. 120 tablets of HC/AP 5/500 from refill prescription
25 number 1264414.

26 xvii. On May 28, 2009, PIC Okimoto furnished to Patient W.H. 120 tablets of
27 HC/AP 5/500 from refill prescription number 1264414, which he should have
28 known was erroneous or uncertain because on May 21, 2009, he had already

1 furnished to Patient W.H. 120 tablets of HC/AP 5/325 from new prescription
2 number 1268675.

3 xviii. On June 23, 2009, PIC Okimoto furnished to Patient W.H. 120 tablets of
4 HC/AP 5/500 from refill prescription number 1264414, which he should have
5 known was erroneous or uncertain because on June 18, 2009, he had already
6 furnished to Patient W.H. 120 tablets of HC/AP 5/500 from new prescription
7 number 1271023.

8 c. From approximately November 3, 2007 to December 23, 2008, PIC Charge Okimoto
9 furnished erroneous or uncertain duplicate prescriptions for HC/AP to Patient K.M. as follows:

10 i. On January 25, 2008, and on February 18, 2008, PIC Okimoto furnished to
11 Patient K.M. 120 tablets of HC/AP 7.5/750 from refill prescription number
12 1231591, which he should have known was erroneous or uncertain because on
13 January 15, 2008, he had already furnished to Patient W.H. 360 tablets of HC/AP
14 5/500 from new prescription number 1236584.

15 ii. On June 10, 2008, PIC Okimoto furnished to Patient K.M. 360 tablets of
16 HC/AP 10/325 from refill prescription number 1244901, which he should have
17 known was erroneous or uncertain because on June 6, 2008, he had already
18 furnished to Patient K.M. 120 tablets of HC/AP 7.5/700 from new prescription
19 number 1246688.

20 iii. On July 10, 2008, PIC Okimoto furnished to Patient K.M. 360 tablets of HC/AP
21 10/325 from refill prescription number 1244901, which he should have known was
22 erroneous or uncertain because on July 6, 2008, he had already furnished to Patient
23 K.M. 120 tablets of HC/AP 7.5/750 from refill prescription number 1246688.

24 iv. On August, 9, 2008, PIC Okimoto furnished to Patient K.M. 360 tablets of
25 HC/AP 10/325 from refill prescription number 1244901, which he should have
26 known was erroneous or uncertain because on August 4, 2008, he had already
27 furnished 120 tablets of HC/AP 7.5/750 to Patient K.M. from refill prescription
28 number 1246688.

1 v. On October 1, 2008, PIC Okimoto furnished to Patient K.M. 120 tablets of
2 HC/AP 7.5/750 from refill prescription number 1246688, which he should have
3 know to be erroneous or uncertain because on September 8, 2008, he had already
4 furnished 360 tablets of HC/AP 10/325 to Patient K.M. from new prescription
5 number 1252056.

6 vi. On October 1, 2008, PIC Okimoto furnished to Patient K.M. 120 tablets of
7 HC/AP 7.5/750 from refill prescription number 1252056, which he should have
8 know to be erroneous or uncertain because on October 1, 2008, he had already
9 furnished 360 tablets of HC/AP 10/325 to Patient K.M. from new prescription
10 number 1246688.

11 vii. On October 27, 2008, PIC Okimoto furnished to Patient K.M. 120 tablets of
12 HC/AP 7.5/750 from new prescription number 1255322, which he should have
13 know to be erroneous or uncertain because on October 1, 2008, he had already
14 furnished 360 tablets of HC/AP 10/325 from refill prescription number 1252056.

15 viii. On October 31, 2008, November 29, 2008, and December 23, 2008, PIC
16 Okimoto furnished to Patient K.M. 360 tablets of HC/AP 10/325 from prescription
17 number 1254729, which he should have know was erroneous or uncertain because
18 on October 27, 2008, he had already furnished to Patient K.M. 120 tablets of HC/AP
19 7.5/750 from prescription number 1255322.

20 SECOND CAUSE FOR DISCIPLINE

21 (Partial Filing of Schedule II Controlled Substances Prescriptions)

22 28. Respondents Highlands and Okimoto are subject to disciplinary action under 16 CCR
23 section 1745, subdivisions (a) and (d), as that section interacts with Code section 4301,
24 subdivision (o), in that Respondent PIC Okimoto partially filled 22 Schedule II controlled
25 substance prescriptions as described below for patients who were not terminally ill or residing in
26 a skilled nursing facility, despite having sufficient quantities on hand to completely fill the
27 prescription. The partially filled prescriptions are as follows:

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

#	Date Dispensed	RX #	Drug	Patient Initials	Quantity Provided	Authorized Quantity
1	12/19/07	1234891	OxyContin 80 mg.	MW	180	270
2	12/20/07	1234891	OxyContin 80 mg.	MW	90	
3	05/21/08	1245640	OxyContin 80 mg.	DW	100	270
4	05/22/08	1245640	OxyContin 80 mg.	DW	100	
5	05/23/08	1245640	OxyContin 80 mg.	DW	70	
6	07/12/08	1248802	OxyContin 80 mg.	MW	90	270
7	07/13/08	1248802	OxyContin 80 mg.	MW	90	
8	07/14/08	1248802	OxyContin 80 mg.	MW	90	
9	07/14/08	1248905	OxyContin 80 mg.	LF	60	180
10	07/15/08	1248905	OxyContin 80 mg.	LF	60	
11	07/16/08	1248905	OxyContin 80 mg.	LF	60	
12	07/24/08	1249470	OxyContin 40 mg.	LF	60	180
13	07/26/08	1249470	OxyContin 40 mg.	LF	50	
14	08/04/08	1249470	OxyContin 40 mg.	LF	10	
15	08/05/08	1249470	OxyContin 40 mg.	LF	40	
16	08/05/08	1249470	OxyContin 40 mg.	LF	20	
17	08/19/08	1251006	OxyContin 80 mg.	KM	125	180
18	08/25/08	1251006	OxyContin 80 mg.	KM	20	
19	08/25/08	1251006	OxyContin 80 mg.	KM	20	
20	08/26/08	1251006	OxyContin 80 mg.	KM	15	
21	08/23/08	1251253	OxyContin 40 mg.	KM	40	180
22	08/25/08	1251253	OxyContin 40 mg.	KM	20	
23	08/26/08	1251253	OxyContin 40 mg.	KM	75	
24	08/27/08	1251253	OxyContin 40 mg.	KM	45	
25	08/27/08	1251458	OxyContin 40 mg.	LF	15	180
26	08/27/08	1251458	OxyContin 40 mg.	LF	30	
27	08/28/08	1251458	OxyContin 40 mg.	LF	30	
28	08/28/08	1251458	OxyContin 40 mg.	LF	20	

29	09/02/08	1251458	OxyContin 40 mg.	LF	85	
30	08/29/08	1251660	OxyContin 80 mg.	LF	70	180
31	09/02/08	1251660	OxyContin 80 mg.	LF	110	

THIRD CAUSE FOR DISCIPLINE

(Failure to Report Controlled Substances to CURES)

29. Respondents Highlands and Okimoto are subject to disciplinary action under Health and Safety Code section 11165, subdivision (d) as that section interacts with Code section 4301, subdivisions (j) and (o), in that from June 2, 2008 to January 16, 2009, Respondent PIC Okimoto failed to report dispensing 46 controlled substance prescriptions to CURES (Controlled Substance Utilization Review and Evaluation System) as follows:

#	Date Dispensed	RX#	New or Refill	Drug	Patient Initials	Quantity
1	06/23/08	1247699	New	Hydrocodone w/Acetaminophen 10/325	DH	30
2	06/25/08	1247699	Refill	Hydrocodone w/Acetaminophen 10/325	DH	30
3	07/11/08	1248768	New	Hydrocodone w/Acetaminophen 10/325	DH	60
4	10/28/08	1252481	New	Hydrocodone w/Acetaminophen 10/325	DH	60
5	07/09/08	1247143	Refill	Hydrocodone w/Acetaminophen 10/325	DW	120
6	07/11/08	1247143	Refill	Hydrocodone w/Acetaminophen 10/325	DW	120
7	07/12/08	1247143	Refill	Hydrocodone w/Acetaminophen 10/325	DW	120
8	06/06/08	1246688	New	Hydrocodone w/Acetaminophen 7.5/750	KM	120
9	07/06/08	1246688	Refill	Hydrocodone w/Acetaminophen 7.5/750	KM	120
10	07/07/08	1248489	New	OxyContin 40 mg.	KM	120
11	07/07/08	1248489	New	OxyContin 40 mg.	KM	60
12	07/10/08	1244901	Refill	Hydrocodone w/Acetaminophen 10/325	KM	360
13	06/02/08	1242692	Refill	Hydrocodone w/Acetaminophen 10/325	LF	360
14	06/04/08	1246585	New	OxyContin 40 mg.	LF	180
15	06/24/08	1247740	New	Hydrocodone w/Acetaminophen 7.5/750	LF	150
16	06/24/08	1247741	New	OxyContin 40 mg.	LF	10
17	06/24/08	1247742	New	Fentanyl 25 mcg. Patch	LF	360

1	18	01/09/09	1256020	Refill	Hydrocodone w/Acetaminophen 10/325	RR	360
2	19	06/02/08	1245850	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
3	20	06/03/08	1245850	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
4	21	06/04/08	1245850	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
5	22	06/05/08	1246669	New	Hydrocodone w/Acetaminophen 10/325	SD	20
6	23	06/06/08	1246669	Refill	Hydrocodone w/Acetaminophen 10/325	SD	55
7	24	06/21/08	1247324	Refill	Hydrocodone w/Acetaminophen 10/325	SD	30
8	25	06/24/08	1247792	New	Hydrocodone w/Acetaminophen 10/325	SD	15
9	26	06/25/08	1247792	Refill	Hydrocodone w/Acetaminophen 10/325	SD	15
10	27	06/26/08	1247792	Refill	Hydrocodone w/Acetaminophen 10/325	SD	15
11	28	06/27/08	1247792	Refill	Hydrocodone w/Acetaminophen 10/325	SD	55
12	29	07/05/08	1248347	Refill	Hydrocodone w/Acetaminophen 10/325	SD	35
13	30	07/07/08	1248347	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
14	31	07/08/08	1248347	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
15	32	07/10/08	1248347	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
16	33	07/11/08	1248761	New	Hydrocodone w/Acetaminophen 10/325	SD	20
17	34	01/03/09	1259274	Refill	Hydrocodone w/Acetaminophen 10/325	SD	30
18	35	01/05/09	1259274	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
19	36	01/07/09	1259846	New	Hydrocodone w/Acetaminophen 10/325	SD	20
20	37	01/08/09	1259846	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
21	39	01/09/09	1259846	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
22	40	01/10/09	1259846	Refill	Hydrocodone w/Acetaminophen 10/325	SD	45
23	41	01/12/09	1259846	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
24	42	01/13/09	1259846	Refill	Hydrocodone w/Acetaminophen 10/325	SD	25
25	43	01/14/09	1260405	New	Hydrocodone w/Acetaminophen 10/325	SD	20
26	44	01/15/09	1260405	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
27	45	01/16/09	1260405	Refill	Hydrocodone w/Acetaminophen 10/325	SD	20
28	46	06/27/08	1247972	New	Hydrocodone w/Acetaminophen 5/500	WH	120
	47	01/13/09	1256539	Refill	Hydrocodone w/Acetaminophen 5/500	WH	120
	TOTAL		46 RXs	16 New RXs, 30 Refill RXs			3.666

1 FOURTH CAUSE FOR DISCIPLINE

2 (Refilling a Controlled Substances Prescription Without Provider Authorization)

3 30. Respondents Highlands and Okimoto are subject to disciplinary action under section
4 4063, as that section interacts with Code section 4301, subdivisions (j) and (o), in that from
5 August 29, 2008 to May 13, 2009, Respondent PIC Okimoto furnished 792 HC/AP 10/325
6 tablets to Patient S.D. without prescriber authorization as follows. Prescription number 1251622
7 authorized a total of 1440 tablets by new and refill prescriptions and 1495 were furnished by
8 Respondent PIC Okimoto, 55 doses more than authorized. Prescription number 1256225
9 authorized a total of 1440 tablets by new and refill prescriptions and 1810 were furnished by
10 Respondent PIC Okimoto, 370 doses more than authorized. And prescription number 1262321
11 authorized a total of 1440 tablets by new and refill prescriptions and 1807 were furnished by
12 Respondent PIC Okimoto, 367 doses more than authorized.

13 FIFTH CAUSE FOR DISCIPLINE

14 (Failure to Keep Records of Disposition)

15 31. Respondents Highland and Okimoto are subject to disciplinary action under Code
16 sections 4081, subdivision (a) and 4105, subdivision (a), as those sections relate to Code section
17 4301, subdivisions (j) and (o); in that Respondent PIC Okimoto, from October 8, 2008 to June 20,
18 2009, failed to make a record of disposition for the following 21 prescriptions, accounting for 570
19 tablets of HC/AP 10/325 furnished to Patient SD, as follows.

20

#	Date Dispensed	RX #	Quantity	Drug
21 1	10/08/08	1253928	15	Hydrocodone with Acetaminophen 10/325 tablets
22 2	10/10/08	1253928	65	Hydrocodone with Acetaminophen 10/325 tablets
23 3	11/11/08	1256225	20	Hydrocodone with Acetaminophen 10/325 tablets
24 4	12/05/08	1257365	65	Hydrocodone with Acetaminophen 10/325 tablets
25 5	12/11/08	1257947	20	Hydrocodone with Acetaminophen 10/325 tablets
26 6	12/13/08	1257947	45	Hydrocodone with Acetaminophen 10/325 tablets

27
28

1	7	12/26/08	1258923	20	Hydrocodone with Acetaminophen 10/325 tablets
2	8	12/29/08	1258923	15	Hydrocodone with Acetaminophen 10/325 tablets
3	9	01/19/09	1260405	20	Hydrocodone with Acetaminophen 10/325 tablets
4	10	01/26/09	1260923	20	Hydrocodone with Acetaminophen 10/325 tablets
5	11	02/26/09	1263073	20	Hydrocodone with Acetaminophen 10/325 tablets
6	12	03/26/09	1265194	20	Hydrocodone with Acetaminophen 10/325 tablets
7	13	03/31/09	1265731	20	Hydrocodone with Acetaminophen 10/325 tablets
8	14	04/17/09	1266766	20	Hydrocodone with Acetaminophen 10/325 tablets
9	15	05/02/09	1267970	45	Hydrocodone with Acetaminophen 10/325 tablets
10	16	05/05/09	1267970	20	Hydrocodone with Acetaminophen 10/325 tablets
11	17	05/11/09	1268401	20	Hydrocodone with Acetaminophen 10/325 tablets
12	18	05/13/09	1268401	20	Hydrocodone with Acetaminophen 10/325 tablets
13	19	05/19/09	1268916	20	Hydrocodone with Acetaminophen 10/325 tablets
14	20	06/02/09	1269579	20	Hydrocodone with Acetaminophen 10/325 tablets
15	21	06/20/09	1271217	40	Hydrocodone with Acetaminophen 10/325 tablets
16		Total	21 RX's	570	Hydrocodone with Acetaminophen 10/325 Tablets

SIXTH CAUSE FOR DISCIPLINE

(Variation From Prescription)

32. Respondents Highland and Okimoto are subject to disciplinary action under section 16 CCR section 1716, as that section relates to Code section 4301, subdivisions (j) and (o), in that on October 13, 2008, Respondent PIC Okimoto dispensed prescription number 1247972 for 120 tablets of HC/AP 5/500 to Patient W.H. before receiving prescriber authorization for the refill. On October 15, 2008, Physicians Assistant Bantea returned the refill request, but changed the directions for use from "1 tablet four times a day" to "1 tablet three times a day" and reduced the quantity from 120 tablets to 90.

///

///

1 ELEVENTH CAUSE FOR DISCIPLINE

2 37. Respondent Okimoto is subject to disciplinary action under Code section 4342; and
3 under Title 21 Code of Federal Regulations sections 211.130, and 211.137, as these sections
4 relate to Code section 4301, subdivisions (j) and (o), as follows. On or about December 26, 2006,
5 Respondent Okimoto failed to ensure that all pre-counted or pre-poured medications were labeled
6 in accordance with current good manufacturing practice requirements and with Health and Safety
7 Code section 11480 of the Sherman Food, Drug and Cosmetic Law in that at the pharmacy there
8 were several pre-counted and poured drugs (Naproxen 500 mg, Soma, Cimetidine 400 mg,
9 Promethazine w/codeine syrup) without any label indicating the name of the drug, the strength of
10 the drug, the dosage form, lot #, expiration date, quantity, or manufacturer's name.

11 TWELFTH CAUSE FOR DISCIPLINE

12 37. Respondent Okimoto is subject to disciplinary action under Code section 4076,
13 subsection (a)(11), and Code section 4077, as those sections relate to Code section 4301,
14 subdivisions (j) and (o), as follows: On or about December 26, 2006, Respondent Okimoto
15 allowed prescription drugs that were ready for pick up to be in containers that did not have
16 attached to them labels that included a physical description of the dispensed medication,
17 including the medication's color, shape, and any identification code that appears on the tablets or
18 capsules

19 PRAYER

20 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
21 and that following the hearing, the Board of Pharmacy issue a decision:

22 1. Revoking or suspending Pharmacy Permit Number PHY 39917, issued to North
23 Highlands Pharmacy;

24 2. Revoking or suspending Pharmacist License Number RPH 24559, issued to Thomas
25 Okimoto;

26 ///


27 ///

28 ///

1 3. Ordering Respondents North Highlands Pharmacy and Thomas Okimoto to pay the
2 Board of Pharmacy the reasonable costs of the investigation and enforcement of this case,
3 pursuant to Business and Professions Code section 125.3;

4 4. Taking such other and further action as deemed necessary and proper.
5

6
7 DATED: 4/9/12



VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

8
9
10
11
12 SA2009102211
13 10804840.doc
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28